
Lixin Guo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/891563/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Time-Restricted Feeding Restored Insulin-Growth Hormone Balance and Improved Substrate and Energy Metabolism in MC4RKO Obese Mice. Neuroendocrinology, 2022, 112, 174-185.	2.5	5
2	Rotating Day and Night Disturb Growth Hormone Secretion Profiles, Body Energy Metabolism, and Insulin Levels in Mice. Neuroendocrinology, 2022, 112, 481-492.	2.5	2
3	Metformin exerts an antitumoral effect on papillary thyroid cancer cells through altered cell energy metabolism and sensitized by BACH1 depletion. Endocrine, 2022, 76, 116-131.	2.3	8
4	The effect of statin adherence on patients with type 2 diabetes after percutaneous coronary intervention for acute coronary syndrome. Cardiovascular Drugs and Therapy, 2022, , 1.	2.6	2
5	Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2022, 13, 826604.	3.5	26
6	Chronic Sleep Deprivation Impaired Bone Formation in Growing Rats and Down-Regulated PI3K/AKT Signaling in Bone Tissues. Nature and Science of Sleep, 2022, Volume 14, 697-710.	2.7	4
7	Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN). Diabetes Therapy, 2022, , .	2.5	2
8	Application of novel subgroups of Chinese inpatients with diabetes based on machine learning paradigm. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102556.	3.6	2
9	Application of new international classification of adultâ€onset diabetes in Chinese inpatients with diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2021, 37, e3427.	4.0	23
10	Glucoseâ€lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology. Diabetes/Metabolism Research and Reviews, 2021, 37, e3416.	4.0	7
11	Iron Deficiency, a Risk Factor of Thyroid Disorders in Reproductive-Age and Pregnant Women: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 629831.	3.5	22
12	Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis. Scientific Reports, 2021, 11, 4131.	3.3	1
13	Association of thyroid disorders with gestational diabetes mellitus: a meta-analysis. Endocrine, 2021, 73, 550-560.	2.3	34
14	Genomeâ€wide profiling of DNA methylation and gene expression unravel the epigenetic landscape in diabetes-related hypothyroidism. Clinical Epigenetics, 2021, 13, 123.	4.1	4
15	Changes in Direct Medical Cost and Medications for Managing Diabetes in Beijing, China, 2016 to 2018: Electronic Insurance Data Analysis. Annals of Family Medicine, 2021, 19, 332-341.	1.9	5
16	Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database. Frontiers in Endocrinology, 2021, 12, 713849.	3.5	2
17	Type 2 Diabetes Mellitus Intersects With Pancreatic Cancer Diagnosis and Development. Frontiers in Oncology, 2021, 11, 730038.	2.8	16
18	The GH-IGF-1 Axis in Circadian Rhythm. Frontiers in Molecular Neuroscience, 2021, 14, 742294.	2.9	7

Lixin Guo

#	Article	IF	CITATIONS
19	TSH Combined with TSHR Aggravates Diabetic Peripheral Neuropathy by Promoting Oxidative Stress and Apoptosis in Schwann Cells. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-23.	4.0	15
20	Metabolic and Nutritional Characteristics in Middle-Aged and Elderly Sarcopenia Patients with Type 2 Diabetes. Journal of Diabetes Research, 2020, 2020, 1-8.	2.3	21
21	Suppression of Insulin Secretion in the Treatment of Obesity: A Systematic Review and Metaâ€Analysis. Obesity, 2020, 28, 2098-2106.	3.0	9
22	Evaluation of the safety of sodiumâ€glucose coâ€ŧransporterâ€2 inhibitors for treating patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1767-1776.	4.4	6
23	Whole grain food diet slightly reduces cardiovascular risks in obese/overweight adults: a systematic review and meta-analysis. BMC Cardiovascular Disorders, 2020, 20, 82.	1.7	25
24	Impaired Mitochondrial Fusion and Oxidative Phosphorylation Triggered by High Glucose Is Mediated by Tom22 in Endothelial Cells. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-23.	4.0	21
25	Prevalence of thyroid dysfunction in older Chinese patients with type 2 diabetes—A multicenter cross-sectional observational study across China. PLoS ONE, 2019, 14, e0216151.	2.5	16
26	Standards of medical care for type 2 diabetes in China 2019. Diabetes/Metabolism Research and Reviews, 2019, 35, e3158.	4.0	404
27	A randomized, open″abel, multicentre, parallelâ€controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study. Diabetes, Obesity and Metabolism. 2018. 20. 2740-2747.	4.4	3
28	In Vivo Corneal Confocal Microscopy Detects Improvement of Corneal Nerve Parameters following Glycemic Control in Patients with Type 2 Diabetes. Journal of Diabetes Research, 2018, 2018, 1-8.	2.3	21
29	Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Therapy, 2017, 8, 727-738.	2.5	55
30	Standards of care for type 2 diabetes in China. Diabetes/Metabolism Research and Reviews, 2016, 32, 442-458.	4.0	236
31	Efficacy and safety of a basal insulin + $2\hat{a}\in 3$ oral antihyperglycaemic drugs regimen versus a twice $\hat{a}\in d$ aily premixed insulin + metformin regimen after short $\hat{a}\in d$ erm intensive insulin therapy in individuals with type 2 diabetes: the multicentre, open $\hat{a}\in d$ abel, randomised controlled <scp>BEYOND$\hat{a}\in V$</scp> trial. Diabetes: O	4.4	2